ECTRIMS 2015 Conference Coverage
Significant differences vs. placebo were maintained over 24 months.
The test can be completed in about one minute and is free to use for clinicians and researchers.
DICAM was strongly linked with expression of ROR-γ, IL-23R, IL-17, IL-22, GM-CSF, and GZMB expression in human CD4+ lymphocytes.
The additional measure of brain volume loss results in a more comprehensive evaluation of disease activity in RRMS.
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
Participants also reported a reduction in anxiety and subjective cognitive impairment.
Compared to those who continued smoking, those who stopped experienced a significant decline in the rate of brain volume loss.
The ratio was also predictive of conversion to secondary-progressive MS.
CSF NfL levels were predictive of brain volume loss at first sign of MS and follow-up.
Spinal cord gray matter atrophy was found to be most relevant compared to other conventional MRI metrics.
Compared to RRMS, progressive MS had greater cord atrophy and lesions.
No significant treatment effect on disease progression or brain or cervical spinal atrophy was observed.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes